Rakuten Medical, Inc.
Tuesday, February 27, 2024
Uris
Oncology
Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox™ technology platform which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Alluminox™ therapies have not yet been approved as safe or effective by any regulatory authority. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives.
State
California
Country
United States
Website
https://rakuten-med.com/us/
CEO/Top Company Official
Hiroshi “Mickey” Mikitani
Lead Product in Development
ASP-1929, conditionally approved in Japan for unresectable or locally recurrent head and neck cancers, concurrently the subject of an FDA-registered Phase 3 clinical trial for 2L+ R HNSCC
Development Phase of Primary Product
Phase III
Number Of Unlicensed Products
3+
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}